Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Reaffirmed by Needham & Company LLC

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research note issued on Thursday, Benzinga reports. They presently have a $200.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price target suggests a potential upside of 31.29% from the company’s current price.

A number of other analysts also recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $395.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, March 5th. Wells Fargo & Company decreased their target price on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a research report on Friday, February 16th. StockNews.com raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 29th. Wolfe Research assumed coverage on Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. Finally, The Goldman Sachs Group downgraded Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $230.00 to $173.00 in a research report on Friday, February 16th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $215.88.

Alnylam Pharmaceuticals Trading Up 1.3 %

Shares of ALNY opened at $152.33 on Thursday. The company has a market capitalization of $19.19 billion, a price-to-earnings ratio of -42.22 and a beta of 0.41. The stock has a 50 day moving average of $149.76 and a 200 day moving average of $165.25. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million for the quarter, compared to analysts’ expectations of $428.01 million. The business’s revenue was up 54.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.40) earnings per share. As a group, equities research analysts predict that Alnylam Pharmaceuticals will post -4.46 earnings per share for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Mediolanum International Funds Ltd bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at $5,953,000. Central Pacific Bank Trust Division bought a new stake in Alnylam Pharmaceuticals during the first quarter worth about $161,000. Daiwa Securities Group Inc. lifted its stake in Alnylam Pharmaceuticals by 1.1% during the first quarter. Daiwa Securities Group Inc. now owns 10,921 shares of the biopharmaceutical company’s stock worth $1,632,000 after purchasing an additional 116 shares during the last quarter. Nordea Investment Management AB lifted its stake in Alnylam Pharmaceuticals by 3.3% during the first quarter. Nordea Investment Management AB now owns 8,980 shares of the biopharmaceutical company’s stock worth $1,365,000 after purchasing an additional 290 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its stake in Alnylam Pharmaceuticals by 7.7% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,849 shares of the biopharmaceutical company’s stock worth $575,000 after purchasing an additional 274 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.